109 results
Page 5 of 6
F-1/A
0qr5l9 5kh
26 Mar 20
Registration statement (foreign) (amended)
12:00am
F-1/A
jlv2k
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
F-1/A
EX-4.7
dhx41
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
F-1
2op1c h3b55ts2wf
31 Jan 20
Registration statement (foreign)
12:00am
6-K
EX-99.1
57lv0
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
424B5
0ilh59uqq
5 Dec 19
Prospectus supplement for primary offering
5:29pm
6-K
EX-10.1
lg4wn
4 Dec 19
Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering
9:26am
6-K
EX-99.1
3h53ujoqx04whh3
13 Nov 19
Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
4:07pm
6-K
EX-99.1
9qaijsuhtkg bury
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
F-3/A
EX-4.2
kh0kf on4a5t1t
29 Aug 19
Shelf registration (foreign) (amended)
4:49pm
6-K
EX-99.1
n9rsf6cb9i a6k6lv
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
6-K
EX-99.1
4h6smj9vz6m1n7t
23 Jul 19
Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a
4:05pm
6-K
EX-99.1
5eq21o58t
18 Jun 19
Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program
4:09pm
424B5
eojep0qiiwk7b
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-10.1
0nqz19oroua90n4 6e32
28 Mar 19
Therapix Biosciences Announces Pricing
8:51am
6-K
EX-99.1
xnhjx27 ofdc917pl
28 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6:27am
6-K
EX-10.3
njt 36zn9o
27 Nov 18
Therapix Biosciences Issues $1,500,000 Convertible Debenture
8:01am
6-K
EX-10.1
wjqdiv8m
27 Nov 18
Therapix Biosciences Issues $1,500,000 Convertible Debenture
8:01am